Article Text

Download PDFPDF
Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening
  1. Marco Cipolli1,
  2. Carlo Castellani1,
  3. Bridget Wilcken2,
  4. John Massie3,
  5. Karen McKay3,
  6. Margie Gruca5,
  7. Anna Tamanini1,
  8. Maurice Baroukh Assael1,
  9. Kevin Gaskin5
  1. 1
    Cystic Fibrosis Centre, Azienda Ospedaliera di Verona, Verona, Italy
  2. 2
    New South Wales Newborn Screening Program, The Children’s Hospital at Westmead, Westmead, NSW, Australia
  3. 3
    Department of Respiratory Medicine, The Children’s Hospital at Westmead, Westmead, NSW, Australia
  4. 5
    James Fairfax Institute of Paediatric Nutrition, Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia
  1. Dr Marco Cipolli, Cystic Fibrosis Centre, Azienda Ospedaliera di Verona, Piazzale Stefani 1, 37126 Verona, Italy;marco.cipolli{at}


Objective: To determine the pancreatic phenotype of infants with cystic fibrosis (CF) diagnosed in the first week of life by a combined immunoreactive trypsin/mutation screening program.

Design: A prospective evaluation of pancreatic function in infants with CF at the time of neonatal diagnosis and up to the age of 12.

Setting: Two different centres (Verona, Italy and Westmead, Australia) to enable comparison of results between two regions where <60% or ⩾90% of patients, respectively, have at least one single ΔF508 a mutation.

Patients: 315 children with CF including 149 at Verona and 166 at Westmead.

Interventions: Fat balance studies over 3–5 days and pancreatic stimulation tests with main outcome measures being faecal fat or pancreatic colipase secretion. Patients with malabsorption are pancreatic insufficient (PI) or with normal absorption and pancreatic sufficient (PS).

Results: 34 infants (23%) at Verona and 46 (28%) at Westmead were PS at diagnosis. 15% of those with two class I, II or III “severe” mutations and 26/28 (93%) of those with class IV or V mutations were PS at this early age. Of the 80 infants with PS, 20 became PI before the age of 12. All 20 had two severe mutations.

Conclusion: Neonatal mutational screening programs for CF are less likely to detect PS patients with non-ΔF508 mutations. Of PS patients who are detected, those with two severe class I, II or III mutations are at particularly high risk of becoming PI during early childhood.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None of the authors have any affiliations, financial agreements or other involvement with any of the companies whose products are mentioned in this manuscript.

  • Abbreviations:
    cystic fibrosis
    cystic fibrosis transmembrane conductance regulator
    immunoreactive trypsin
    meconium ileus
    pancreatic insufficient
    pancreatic sufficient
    pancreatic stimulation test

Linked Articles